<DOC>
	<DOCNO>NCT01422304</DOCNO>
	<brief_summary>This study assess effect reversal neuromuscular blockade sugammadex compare reversal accord usual care ( neostigmine spontaneous reversal ) incidence post-surgical bleeding event coagulation parameter participant undergo hip fracture surgery joint ( hip/knee ) replacement surgery neuromuscular blockage induce rocuronium vecuronium .</brief_summary>
	<brief_title>Reversal Neuromuscular Blockade With Sugammadex Usual Care Hip Fracture Surgery Joint ( Hip/Knee ) Replacement ( P07038 )</brief_title>
	<detailed_description>Participants randomize sugammadex usual care 1:1 ratio .</detailed_description>
	<mesh_term>Hip Fractures</mesh_term>
	<mesh_term>Atropine</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<mesh_term>Neostigmine</mesh_term>
	<mesh_term>Vecuronium Bromide</mesh_term>
	<mesh_term>Rocuronium</mesh_term>
	<criteria>Must American Society Anesthesiologists ( ASA ) Class 1 , 2 , 3 Must schedule hip fracture surgery joint ( hip knee ) replacement surgery general anesthesia include use rocuronium vecuronium neuromuscular blockade Must : Currently receive thromboprophylactic ( anticlotting ) therapy low molecular weight heparin ( LMWH ) unfractionated heparin ( UFH ) , Planned initiate thromboprophylactic therapy LMWH UFH prior surgery , Currently receive ongoing thromboprophylactic therapy vitamin K antagonist temporarily substitute perioperative LMWH UFH , and/or Currently receive ongoing thromboprophylactic therapy lowdose aspirin antiplatelet therapy Platelet count lower limit normal range Appropriate candidate rapid reversal neuromuscular blockade Sexually active female must agree use medically accept method contraception seven day receive protocolspecified medication Anatomical malformation may lead difficult intubation Neuromuscular disorder may affect neuromuscular blockade History coagulation disorder , bleed diathesis , systemic lupus erythematosus antiphospholipid syndrome History evidence active abnormal bleeding blood clot within 30 day prior screen Significant hepatic dysfunction Severe renal insufficiency History family history malignant hyperthermia Hypersensitivity hypersensitivitylike reaction sugammadex , muscle relaxant , medication use general anesthesia Planned intravenous administration toremifene and/or fusidic acid within 24 hour within 24 hour study medication Recent , severe trauma Body Mass Index ( BMI ) &gt; 35 Any contraindication administration sugammadex neostigmine/glycopyrrolate ( neostigmine/atropine ) Pregnant intend become pregnant randomization Day 30 followup visit Breastfeeding Previously treat sugammadex participate sugammadex clinical trial Has active hip/knee infection schedule revision surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>